BALOFLOXACIN DIHYDRATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H24FN3O4.2H2O
Molecular Weight	425.4512
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.CNC1CCCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O

InChI

InChIKey=WEGNYJXOCPJAPS-UHFFFAOYSA-N

InChI=1S/C20H24FN3O4.2H2O/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27;;/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27);2*1H2

HIDE SMILES / InChI

Description
Sources: http://www.tabletwise.com/baloxin-tablet
Curator's Comment: description was created based on several sources, including: https://www.medicineindia.org/pharmacology-for-generic/2923/balofloxacin http://www.ajptr.com/archive/volume-2/february-2012-issue-1/article-92.html

Balofloxacin (Q-35), is an orally active fluoroquinolone antibiotic. It has been developed for the treatment of urinary tract infection. The bactericidal action of Balofloxacin results from interference with the enqyme DNA gyrase which is needed for the synthesis of bacterial DNA. Balofloxacin is efficacious against Gram-negative bacteria. It also has enhanced activity against Gram positive bacteria, including MRSA and Streptococcus pneumoniae. Side effects of Balofloxacin are: sensitivity to light, abdominal pain, nausea, heartburn, urticarial, irritation when applied locally. Balofloxacin may interact with the following medicines and salts: antacids, non-steroidal anti-inflammatory drug, quinolones, theophylline.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8000379	Inhibitor 8297
Topoisomerase IV subunit A 7 Target ID: CHEMBL1895 Sources: http://www.ncbi.nlm.nih.gov/pubmed/19478540	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Urinary tract infections 205 Sources: https://www.medchemexpress.com/DataSheet/balofloxacin.html https://www.ncbi.nlm.nih.gov/pubmed/12669387	Curative	Approved 8429	Q-Roxin Approved Use Treatment of uncomplicated urinary tract infections Launch Date 2000
Respiratory tract infections 85 Sources: https://www.medchemexpress.com/DataSheet/balofloxacin.html	Curative	Phase II 1132	Unknown Approved Use Unknown
Infective ophthalmitis 2 Sources: https://www.1mg.com/generics/balofloxacin-209419	Curative	Approved 8429	Barofloxacin Approved Use Barofloxacin is a quinolone antibiotic, prescribed for the treatment of infective ophthalmitis.
Skin infections 59 Sources: https://www.1mg.com/generics/balofloxacin-209419	Curative	Approved 8429	Balofloxacin Approved Use Barofloxacin is a quinolone antibiotic, prescribed for the treatment of skin infections.

PubMed

Title	Date	PubMed
[In vitro anti-MAC activities of new quinolones in focus (2)].	1996 Sep	8999137
History of quinolones and their side effects.	2001	11549783
Aquatic photochemistry of fluoroquinolone antibiotics: kinetics, pathways, and multivariate effects of main water constituents.	2010 Apr 1	20205456

Patents

Sample Use Guides

In Vivo Use Guide

100 to 400 mg once or twice daily.

Route of Administration: Oral

In Vitro Use Guide

MIC90 of Balofloxacin against clinical isolates of Staphylococcus aureus, methicillin-resistant staphylococcus aureus (MRSA), Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes is 6,25 ug/ml.

Name

Type

Language

BALOFLOXACIN DIHYDRATE

Common Name

English

3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(3-(METHYLAMINO)-1-PIPERIDINYL)-4-OXO-, DIHYDRATE, (±)-

Common Name

English

3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(3-(METHYLAMINO)-1-PIPERIDINYL)-4-OXO-, (±)-, DIHYDRATE

Common Name

English

(±)-1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(3-(METHYLAMINO)PIPERIDINO)-4-OXO-3-QUINOLINECARBOXYLIC ACID, DIHYDRATE

Common Name

English

BALOFLOXACIN HYDRATE

Common Name

English

BALOFLOXACIN HYDRATE [JAN]

Common Name

English

3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-8-METHOXY-7-(3-(METHYLAMINO)-1-PIPERIDINYL)-4-OXO-, DIHYDRATE

Common Name

English

Code System Code Type Description

PUBCHEM

6918202

Created by admin on Sat Dec 16 06:16:54 GMT 2023 , Edited by admin on Sat Dec 16 06:16:54 GMT 2023

PRIMARY

FDA UNII

SH1AVB6TVK

Created by admin on Sat Dec 16 06:16:54 GMT 2023 , Edited by admin on Sat Dec 16 06:16:54 GMT 2023

PRIMARY

CAS

151060-21-8

Created by admin on Sat Dec 16 06:16:54 GMT 2023 , Edited by admin on Sat Dec 16 06:16:54 GMT 2023

PRIMARY

ACTIVE MOIETY


					Q022B63JPM

BALOFLOXACIN

SUBSTANCE RECORD


					SH1AVB6TVK

BALOFLOXACIN DIHYDRATE

Details

SMILES

InChI

DescriptionSources: http://www.tabletwise.com/baloxin-tabletCurator's Comment: description was created based on several sources, including: https://www.medicineindia.org/pharmacology-for-generic/2923/balofloxacin http://www.ajptr.com/archive/volume-2/february-2012-issue-1/article-92.html

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Approved Use

Approved Use

PubMed

Patents

Sample Use Guides

Description
Sources: http://www.tabletwise.com/baloxin-tablet
Curator's Comment: description was created based on several sources, including: https://www.medicineindia.org/pharmacology-for-generic/2923/balofloxacin http://www.ajptr.com/archive/volume-2/february-2012-issue-1/article-92.html